You are using an outdated browser. We suggest you update your browser for a better experience. Click here for update.
Close this notification.
Skip to main content Skip to search

 

17 Results
Drug
Other Name(s): Femara®
May 2022
Drug
Other Name(s): Tykerb®
Dec 2022
Regimen
Intent: Adjuvant
Funding:
ODB - General Benefit
    letrozole
Nov 2020
Regimen
Intent: Palliative
Funding:
ODB - General Benefit
    letrozole
Nov 2020
Regimen
Cancer Type:
Hematologic, 
Myelodysplastic Syndrome (MDS)
Intent: Palliative
Funding:
ODB Limited Use
    lenalidomide - For the treatment of patients with anemia due to myelodysplastic syndrome (MDS), according to clinical criteria
May 2022
Regimen
Cancer Type:
Hematologic, 
Multiple Myeloma
Intent: Palliative
Funding:
ODB Limited Use
    lenalidomide - For the maintenance treatment of patients with newly diagnosed multiple myeloma, following ASCT, according to clinical criteria
May 2022
Regimen
Cancer Type:
Gynecologic, 
Ovary
Intent: Palliative
Funding:
ODB - General Benefit
    letrozole
Nov 2020
Regimen
Cancer Type:
Endocrine, 
Thyroid
Intent: Palliative
Funding:
Exceptional Access Program
    lenvatinib - For the treatment of patients with locally recurrent or metastatic, progressive, radioactive-iodine-refractory differentiated thyroid cancer (DTC) according to criteria
Sep 2020
Regimen
Cancer Type:
Hematologic, 
Lymphoma - Non-Hodgkin's High Grade
Intent: Palliative
May 2022
Regimen
Cancer Type:
Hematologic, 
Lymphoma - Non-Hodgkin's High Grade
Intent: Curative
May 2022
Regimen
Cancer Type:
Genitourinary, 
Renal cell / Kidney
Intent: Palliative
Sep 2020
Guidelines and Advice
Status: Current
ID: GL 8-10
Version: N/A
Feb 2020

Pages